Literature DB >> 34693726

Patient Experiences with Telemedicine for HIV Care During the First COVID-19 Wave in Atlanta, Georgia.

Karla I Galaviz1, N Sarita Shah2,3, Mariana Gutierrez3, Lauren F Collins2,4, Cecile D Lahiri2,4, Caitlin A Moran2,4, Brittany Szabo4, Jeri Sumitani4, Jeselyn Rhodes5, Vincent C Marconi2,3,4, Minh Ly Nguyen2,4, Valeria D Cantos2,4, Wendy S Armstrong2,4, Jonathan A Colasanti2,3,4.   

Abstract

We explored experiences with telemedicine among persons with HIV (PWH) during the first wave of the coronavirus disease 2019 (COVID-19) pandemic. A convenience sample of adults (>18 years) receiving care in an urban clinic in Atlanta were invited to participate. Patients completed a structured survey that assessed the usefulness, quality, satisfaction, and concerns with telemedicine services (telephone calls) received during the first wave of the COVID-19 pandemic (March-May 2020). Demographic, plasma HIV-1 RNA, and CD4+ T cell count data were obtained through medical chart abstraction. Bootstrapped t-tests and chi-square tests were used to examine differences in patient experiences by age, sex, and race. Of 406 PWH contacted, 101 completed the survey (median age 55 years, 84% men, 77% Black, 98% virally suppressed, median CD4 count 572 cells/μL). The main HIV care disruptions experienced were delays in follow-up visits (40%), difficulty getting viral load measured (35%), and difficulty accessing antiretroviral therapy (21%). Participant ratings for quality (median score 6.5/7), usefulness (median score 6.0/7), and satisfaction (median score 6.3/7) with telemedicine were high. However, 28% of patients expressed concerns about providers' ability to examine them and about the lack of laboratory tests. More women had concerns about providers' ability to examine them (92% vs. 50%, p = .005) and about the safety of their personal information (69% vs. 23%, p = .002) compared with men. No age or race differences were observed. Although PWH are generally satisfied with telephone-based telemedicine, concerns with its use were notable, particularly among women. Future HIV telemedicine models should address these.

Entities:  

Keywords:  health services research; implementation; quality improvement; telehealth

Mesh:

Year:  2021        PMID: 34693726      PMCID: PMC9206466          DOI: 10.1089/AID.2021.0109

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   1.723


  17 in total

1.  Exploring the Attitude of Patients with HIV About Using Telehealth for HIV Care.

Authors:  Dima Dandachi; Bich N Dang; Brandon Lucari; Michelle Teti; Thomas P Giordano
Journal:  AIDS Patient Care STDS       Date:  2020-04       Impact factor: 5.078

2.  Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.

Authors:  Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde
Journal:  J Biomed Inform       Date:  2008-09-30       Impact factor: 6.317

3.  Using survey methods in telehealth research: A practical guide.

Authors:  Danette Langbecker; Liam J Caffery; Nicole Gillespie; Anthony C Smith
Journal:  J Telemed Telecare       Date:  2017-07-20       Impact factor: 6.184

4.  Predictors of Adult Retention in HIV Care: A Systematic Review.

Authors:  Shiraze M Bulsara; Milton L Wainberg; Toby R O Newton-John
Journal:  AIDS Behav       Date:  2018-03

5.  Addressing evolving patient concerns around telehealth in the COVID-19 era.

Authors:  Minakshi Raj; Matthew J DePuccio; Amber L Stephenson; Erin Sullivan; Alden Yuanhong Lai; Bram Fleuren; Abi Sriharan; Ann Scheck McAlearney; Samuel C Thomas
Journal:  Am J Manag Care       Date:  2021-01-01       Impact factor: 2.229

6.  Social Support and "Playing Around": An Examination of How Older Adults Acquire Digital Literacy With Tablet Computers.

Authors:  Hsin-Yi Sandy Tsai; Ruth Shillair; Shelia R Cotten
Journal:  J Appl Gerontol       Date:  2015-10-21

7.  COVID-19, Telemedicine, and Patient Empowerment in HIV Care and Research.

Authors:  Ofole Mgbako; Emily H Miller; Anthony F Santoro; Robert H Remien; Noga Shalev; Susan Olender; Peter Gordon; Magda E Sobieszczyk
Journal:  AIDS Behav       Date:  2020-07

8.  Innovations in Human Immunodeficiency Virus (HIV) Care Delivery During the Coronavirus Disease 2019 (COVID-19) Pandemic: Policies to Strengthen the Ending the Epidemic Initiative-A Policy Paper of the Infectious Diseases Society of America and the HIV Medicine Association.

Authors:  Wendy S Armstrong; Allison L Agwu; Ernie-Paul Barrette; Rachel Bender Ignacio; Jennifer J Chang; Jonathan A Colasanti; Michelle Floris-Moore; Marwan Haddad; Lynsay MacLaren; Andrea Weddle
Journal:  Clin Infect Dis       Date:  2021-01-23       Impact factor: 9.079

9.  Beyond viral suppression of HIV - the new quality of life frontier.

Authors:  Jeffrey V Lazarus; Kelly Safreed-Harmon; Simon E Barton; Dominique Costagliola; Nikos Dedes; Julia Del Amo Valero; Jose M Gatell; Ricardo Baptista-Leite; Luís Mendão; Kholoud Porter; Stefano Vella; Jürgen Kurt Rockstroh
Journal:  BMC Med       Date:  2016-06-22       Impact factor: 8.775

10.  Intersecting Pandemics: Impact of SARS-CoV-2 (COVID-19) Protective Behaviors on People Living With HIV, Atlanta, Georgia.

Authors:  Seth C Kalichman; Lisa A Eaton; Marcie Berman; Moira O Kalichman; Harold Katner; Soya S Sam; Angela M Caliendo
Journal:  J Acquir Immune Defic Syndr       Date:  2020-09-01       Impact factor: 3.771

View more
  1 in total

1.  Impact of Multicomponent Support Strategies on Human Immunodeficiency Virus Virologic Suppression Rates During Coronavirus Disease 2019: An Interrupted Time Series Analysis.

Authors:  Matthew A Spinelli; Noelle Le Tourneau; David V Glidden; Ling Hsu; Matthew D Hickey; Elizabeth Imbert; Mireya Arreguin; Jennifer P Jain; Jon J Oskarsson; Susan P Buchbinder; Mallory O Johnson; Diane Havlir; Katerina A Christopoulos; Monica Gandhi
Journal:  Clin Infect Dis       Date:  2022-08-24       Impact factor: 20.999

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.